Cellectar Biosciences, Inc.
NCM: CLRBLive Quote
📈 ZcoreAI Score
Our AI model analyzes Cellectar Biosciences, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get CLRB Z-Score →About Cellectar Biosciences, Inc.
Healthcare
Biotechnology
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
📊 Fundamental Analysis
Cellectar Biosciences, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -170.3%, which indicates that capital utilization is currently under pressure.
At a current price of $2.76, CLRB currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $2.43 - $20.70).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$11.70M
Trailing P/E
--
Forward P/E
-0.89
Beta (5Y)
0.40
52W High
$20.70
52W Low
$2.43
Avg Volume
42K
Day High
Day Low